Gemcitabine in non-small cell lung cancer

Bibliography

• NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. (1995) 311:899–909.
   PubMed Web of Science ®Google Scholar
• •First study demonstrating a statistically significant advantage for platinum-based chemotherapy in advanced NSCLC.
   Google Scholar
• LUUD B, KRISTJANSON PEG, HANSEN HH: Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). Cancer Treat. Rev. (1994) 19:45–55.
   Google Scholar
• GATZEMEIER U, SHEPHERD F, LE CHEVALIER T et al.: Activity of gemcitabine in patients with nonsmall cell lung cancer: a multicenter, extended Phase II study. Eur.J Cancer (1996) 32A:243–248.
   Google Scholar
• ABRATT RP, BEZWODA WR, FALKSON G et al.: Efficacy and safety profile of gemcitabine in nonsmall cell lung cancer: a Phase II study. j Clin. °flea (1994) 12:1535–1540.
   PubMed Web of Science ®Google Scholar
• ANDERSON H, HOP WOOD P, STEPHENS RI et al.: Gemcitabine plus best supportive care (BSC) versus BSC in inoperable nonsmall cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br. Cancer (2000) 83:447–453.
   PubMedGoogle Scholar
• CARDENAL F, LOPEZ-CABRERIZO M,ANTON A et al.: Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. j. Clin. °flea (1999) 17:12–18.
   Google Scholar
• CRINO L, SCAGLIOTTI GV, RICCI S etal.: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized Phase III study of the Italian Lung Cancer Project.j Clin. °flea (1999) 17:3522–3530.
   Google Scholar
• SANDLER A, NEMUNAITIS J, DEHNAM C et al.: Phase III study of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic nonsmall cell lung cancer. j. Clin. °flea (2000) 18:122–130.
   PubMed Web of Science ®Google Scholar
• SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl.' Med. (2002) 346:92–98.
   PubMed Web of Science ®Google Scholar
• •Large, randomised trial demonstrating equivalence of new platinum-based chemotherapies in advanced NSCLC.
   Google Scholar
• SCAGLIOTTI GV, DE MARINIS F, RINALDI M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced nonsmall cell lung cancer. Proc. Am. Soc. Clin. °flea (2001) 19:A1227.
   Google Scholar
• ABRATT RP, BEZWODA WP, GOEDHALS L, HACKING DJ: Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced nonsmall-cell lung cancer. j Clin. °flea (1997) 15:744–749.
   PubMed Web of Science ®Google Scholar
• RINALDI M, CRINO L, SCAGLIOTTI GV et al.: A three-week schedule of gemcitabine-cisplatin in advanced nonsmall-cell lung cancer with two different cisplatin dose levels: a Phase II randomized trial. Ann. OncoL (2000) 11:1295–1300.
   PubMedGoogle Scholar
• NG EW, SANDLER AB, EINHORN LH et al.: A Phase II study of carboplatin plus gemcitabine in non small-cell lung cancer (NSCLC). Proc. Am. Soc. Gin. OncoL (1998) 17:468a.
   Google Scholar
• CARRATO A, ALBEROLA V, MASSUTI B et al.: Combination of gemcitabine and carboplatin as first-line treatment in nonsmall-cell lung cancer. Ann. °flea (1998) 9:89. Abstract 431P.
   Google Scholar
• EDELMAN MJ, GANDARA DR, LAU DH et al.: Sequential combination chemotherapy in patients with advanced non small cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer (2001) 92:146–152.
   PubMedGoogle Scholar
• EDELMAN MJ, CLARK JI, CHANSKY Ket al.: Randomized Phase II trial of sequential chemotherapy in advanced nonsmall cell lung cancer (swog 9806): carboplatin/gemcitabine (Carb/G) followed by paclitaxel (P) or cisplatin/vinorelbine (C/ V) followed by docetaxel (D). Proc. Am. Soc. Clin. °flea (2001) 20:314a.
   Google Scholar
• DANSON S, CLEMONS M, MIDDLETON M et al.: A randomised study of gemcitabine with carboplatin (GC) versus mitomycin, vinblastine and cisplatin (MVP) or mitomycin c, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced nonsmall cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Onco1 (2001) 20:322a.
   Google Scholar
• A Phase III study in advanced nonsmall celllung cancer (NSCLC) comparing gemcitabine (G) with gemcitabine in combination with carboplatin (C). Data from an ongoing study by the Swedish Lung Cancer Study Group (SLUSG). Proc. Am. Soc. Clin. °flea (2001) 20:324a.
   Google Scholar
• MANEGOLD C, BERGMAN B, CHEMAISSANI A et al.: Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised Phase II study in locally advanced or metastatic nonsmall-cell lung cancer. Ann. °flea (1997) 8:525–529.
   Google Scholar
• PERNG RP, CHEN YM, MING-LIU J etal.: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable nonsmall-cell lung cancer in a Phase II randomized study. j Clin. °flea (1997) 15:2097–2102.
   Google Scholar
• VANSTEENKISTE J, VANDEBROEK J, NACKAERTS K et al.: Gemcitabine monotherapy versus cisplatin-based chemotherapy in symptomatic advanced NSCLC: a prospective randomized comparison of symptom control. Lung Cancer (2001) 29 (Suppl. 1) :48.
   Google Scholar
• GEORGOULIAS V, PAPADAKIS E, ALEXOPOULOS A et al.: Platinum-based and non-platinum-based chemotherapy in advanced nonsmall-cell lung cancer: a randomised multicentre trial. Lancet (2001) 357:1478–1484.
   PubMed Web of Science ®Google Scholar
• •First trial demonstrating equivalence of platinum-based with non-platinum-based chemotherapy.
   Google Scholar
• KOSMIDIS PA, BACOYIANNIS C, MYLONAKIS N et al.: A randomized Phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non small-cell lung cancer. A preliminary analysis. Proc. Am. Soc. Clin. °flea (2000) 19:A488.
   Google Scholar
• VAN MEERBEECK JP, SMIT EF, LIANES P et al.: A EORTC randomized Phase III trial of three chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC). Proc. Am. Soc. Clin. °flea (2000) 19:A1228.
   Google Scholar
• KRAJNIK G, MOHN-STAUDNER A, THALER J et al.: Vinorelbine-gemcitabine in advanced nonsmall-cell lung cancer (NSCLC): an AASLC Phase II trial. Austrian Association for the Study of Lung Cancer. Ann. °flea (2000) 11:993–998.
   Google Scholar
• CHEN YM, PERNG RP, YANG KY et al.: A multicenter Phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) nonsmall cell lung cancer. Chest (2000) 117:1583–1589.
   PubMed Web of Science ®Google Scholar
• KRAJNIK G, WEIN W, GREIL R et al.: Vinorelbine/gemcitabine in advanced nonsmall cell lung cancer (NSCLC): a Phase I trial. Ear. Cancer (1998) 34:1977–1980.
   PubMedGoogle Scholar
• ISOKANGAS OP, KNUUTTILA A, HALME M et al: Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV nonsmall-cell lung cancer. Ann. Omni (1999) 10:1059–1063.
   Google Scholar
• GRIDELLI C, FRONTINI L, PERRONE F et al.: Gemcitabine plus vinorelbine in advanced nonsmall cell lung cancer: a Phase II study of three different doses. Gem Vin Investigators. Br. Cancer (2000) 83:707–714.
   Google Scholar
• GRIDELLI C, CIGOLARI S, GALLO C etal.: Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced nonsmall-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer (2001) 31:277–284.
   Google Scholar
• BERETTA GD, MICHETTI G, BELOMETTI MO et al.: Gemcitabine plus vinorelbine in elderly or unfit patients with nonsmall cell lung cancer. Br. Cancer (2000) 83:573–576.
   Google Scholar
• HERBST RS, LILENBAUM R: Gemcitabine and vinorelbine combinations in the treatment of nonsmall cell lung cancer. Semin. Omni (1999) 26\(Suppl. 16):67–70.
   Google Scholar
• GRIDELLI C, PERRONE F, CIGOLARI S et al.: The MILES (Multicenter Italian Lung Cancer in the Elderly Study) Phase III trial: gemcitabine + vinorelbine versus vinorelbine and versus gemcitabine in elderly advanced NSCLC patients. Proc. Am. Soc. Clin. Oncol (2001) 20:A1230.
   Google Scholar
• •Trial demonstrating that single-agent chemotherapy is preferable in elderly NSCLC patients.
   Google Scholar
• BUDMAN DR, CALABRO A, KREIS W: In vitro evaluation of synergism or antag-onism with combinations of new cytotoxic agents. Anticancer Drugs (1998) 9:697–702.
   PubMed Web of Science ®Google Scholar
• COMELLA P, FRASCI G, PANZA Net al.: Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a Phase III trial of the Southern Italy Cooperative Oncology Group. J. Clin. Omni (2000) 18:1451–1457.
   Google Scholar
• COMELLA P; SOUTHERN ITALY COOPERATIVE ONCOLOGY GROUP: Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer. Semin. Oncol (2001) 28\(Suppl. 7):7–10.
   Google Scholar
• HUSSEIN A, BIRCH R, WALLER J et al: Preliminary results of a randomized study comparing pacfitaxel and carboplatin (PC) with or without gemcitabine (G) in newly diagnosed non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2000) 19:A1973.
   Google Scholar
• GREEN M: Lung cancer: small cell and non-small cell. In: 2001 Annual Meeting Summaries. American Society of Clinical Oncology Johnson DH (Ed.), Alexandria (2001):68–70.
   Google Scholar
• ALBEROLA V, CAMPS C, PRO VENCIA M et al: Cisplatin/gemcitabine (CG) versus cisplatin/gemcitabine/vinorelbine (CGV) versus sequential doublets of gemcitabine/ vinorelbine followed by ifosfamide/ vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): results of a Spanish Lung Cancer Group Phase III trial (GEPC/98-02). Proc. Am. Soc. Clin. Oncol (2001) 20:A1229.
   Google Scholar
• •Randomised trial demonstrating the lack of superiority of three-drug regimens versus standard doublets.
   Google Scholar
• GRIDELLI C: The ELVIS trial: a Phase III study of single-agent vinorelbine as first-fine treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist (2001) 6\(Suppl. 1):4–7.
   Google Scholar
• LANGER C, MANOLA Y, BERNARDO P et al.: Advanced age alone does not compromise outcome in fit non small-cell lung cancer (NSCLC) patients receiving platinum-based therapy: Implication of ECOG 5592. Proc. Am. Soc. Clin. Omni (2000) 19:A489.
   Google Scholar
• SHEPHERD FA, ABRATT RP, ANDERSON H et al: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin. Omni (1997) 24\(Suppl. 7):50–55.
   Google Scholar
• FRASCI G, LORUSSO V, PANZA Net al.: gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin. Oncol (2000) 18:2529–2536.
   Google Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.j Clin. Omni (2000) 18:2095-2103. Trial demonstrating efficacy of docetaxel as second-line chemotherapy in advanced NSCLC.
   Google Scholar
• FOSSELLA FV, DEVORE R, KERR RN etal.: Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. Clin. Oncol (2000) 18:2354–2362.
   Google Scholar
• •Trial demonstrating efficacy of docetaxel as second-line chemotherapy in advanced NSCLC.
   Google Scholar
• VAN KOOTEN M, TRAINE G, CINAT G et al.: Single-agent gemcitabine in pretreated patients with non-small cell lung cancer: results of an Argentinean multicentre Phase II trial. Br. Cancer (1999) 81:846–849.
   Google Scholar
• CRINO L, MOSCONI AM, SCAGLIOTTI GV et al.: Gemcitabine as second-fine treatment for advanced non-small cell lung cancer:a Phase II trial. Clin. Oncol (1999) 17:2081–2085.
   Google Scholar
• BAAS P, CODRINGTON H, MULLER M et al.: Second line gemcitabine (GEM) therapy in non-small cell lung cancer (NSCLC) stage IIIB and IV Proc. Am. Soc. Clin. Oncol (1999) 18:495a. Abstract 1911.
   Google Scholar
• ROSSI A, PERRONE F, BARLETTA E etal.: Activity of gemcitabine (GEM) in cisplatin-pretreated patients with advanced non-small cell lung cancer (NSCLC): a Phase II trial. Proc. Am. Soc. Clin. Omni 18:484a. Abstract 1868.
   Google Scholar
• GARFIELD DH, DAKHIL SR, WHITTAKER TL et al.: Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer (ANSCLC). Proc. Am. Soc. Clin. Oncol (1998) 17:484a. Abstract 1863.
   Google Scholar
• CASSANO A, CORSI DC, POZZO C et al.: Gemcitabine as rescue treatment of advanced non-small cell lung cancer: Effect on brain metastasis. Ann. Oncol (1998) 9 (Suppl. 2):163. Abstract.
   Google Scholar
• GUERRA AJ, ARCED IANO A, CASTELLANO D et al.: Improvement of disease-related symptoms with second-fine of gemcitabine in advanced non-small cell 752 lung cancer. Ann. °flea (1998) 9\(Suppl. 4):94. Abstract.
   Google Scholar
• REDDY GR, GANDARA DR, EDELMAN MJ et al.: Gemcitabine (GEM) in platinum (PLAT) treated non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (1999) 18:521a. Abstract 2007.
   Google Scholar
• ROSVOLD E, LANGER CJ, SCHILDER R et al: Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel. Proc. Am. Soc. Clin. Oncol (1998) 17:467a. Abstract 1797.
   Google Scholar
• BIESMA B, SMIT EF, POSTMUS PE: A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy. Lung Cancer (1999) 24:115–121.
   PubMed Web of Science ®Google Scholar
• COLE JL, RINALDI DA, LORMAND NA et al.: A Phase I-II trial of topotecan (TOP) and gemcitabine (GEM) for patients with previously treated, advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (1999) 18:499a. Abstract 1927.
   Google Scholar
• HERRERO CC, MARTINEZ EN, JAIME AB: Second-line treatment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures: a pilot study. Lung Cancer (2000) 27:47–53.
   PubMedGoogle Scholar
• GIAN V, HAINSWORTH JD, BURRIS HA et al.: Combination gemcitabine and vinorelbine in the second-line treatment of non-small cell lung cancer (NSCLC): a Phase II study of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol (1999) 18:505a. Abstract 1949.
   Google Scholar
• HERBST RS, KHURI FR, JUNG M et al:Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol (1999) 18:462a. Abstract 1782.
   Google Scholar
• BARR F, MIRSKY H, CLINTHORNE D et al.: A Phase III study of gemcitabine and vinorelbine salvage chemotherapy for taxane resistant non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (1999) 18:496a. Abstract 1914.
   Google Scholar
• BLUMENSCHEIN GR, KHURI FR, FOSSELLA FV et al.: Final report of the M.D. Anderson Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol (2001) 20:344a. Abstract 1371.
   Google Scholar
• TSAVARIS N, KOSMAN C, VADIAKA M et al.: Gemcitabine and docetaxel as second-line chemotherapy in non-small cell lung cancer (NSCLC) failing prior paclitaxel plus platinum-based regimens. Proc. Am. Soc. Clin. Oncol (2001) 20:341a. Abstract 1360.
   Google Scholar
• GOOR C, SCALLIET P, VAN MEERBEEK Jet al.: A Phase II study combining gemcitabine with radiotherapy in stage III NSCLC. Ann. Oncol (1996) 7:101. Abstract 481.
   Google Scholar
• GREGOR A, PRICE A, VAN DER LEESTAHD et al.: Phase I study of gemcitabine and radiotherapy in stage III non small-cell lung cancer. Proc. Am. Soc. Clin. Oncol (1999) 18. Abstract 1953.
   Google Scholar
• ZINNER RG, FOSSELLA FV, KOMAK R et al.: Gemcitabine with concurrent 3D conformal radiation followed by consolidation gemcitabine plus cisplatin; a Phase I trial for patients with Stage III non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2000) 19. Abstract 1996.
   Google Scholar
• BLACKSTOCK AW, LESSER GJ, FLETCHER-STEEDE J et al.: Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small cell lung cancer. Int. I Radial-. Oncol Biol. Phys. (2001) 51:1281–1289.
   PubMedGoogle Scholar
• VOKES EE, LEOPOLD KA, HERNDON JE: A randomized Phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer (CALGB Study 9431). Proc. Am. Soc. Clin. Oncol (1999) 18:A1771.
   Google Scholar
• TRODELLA L, GRANONE P, VALENTE S et al.: Phase I Trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small cell lung cancer. Clin. Oncol (2002) 20:804–810.
   Google Scholar